Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
80%(4 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_3
1
13%
Ph phase_4
4
50%
Ph phase_2
1
13%

Phase Distribution

0

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
4(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(1)
Other(2)

Detailed Status

Completed5
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 44 (66.7%)

Trials by Status

completed563%
unknown225%
terminated113%

Recent Activity

0 active trials
Showing 5 of 8
completed

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry

NCT00844285
unknownphase_4

Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity

NCT02466581
unknownphase_4

Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction

NCT01491815
completedphase_2

Study of Cimzia for the Treatment of Ulcerative Colitis

NCT01090154
completed

Novel Imaging Markers for Rheumatoid Arthritis

NCT01773681
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00844285

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry

Completed
NCT02466581Phase 4

Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity

Unknown
NCT01491815Phase 4

Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction

Unknown
NCT01090154Phase 2

Study of Cimzia for the Treatment of Ulcerative Colitis

Completed
NCT01773681

Novel Imaging Markers for Rheumatoid Arthritis

Completed
NCT00552344Phase 3

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Completed
NCT01696942Phase 4

Cimzia Versus Mesalamine for Crohn's Recurrence

Terminated
NCT01147341Phase 4

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

Completed

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8